1. The anesthesia drug market is likely to grow 2.5 percent from 2009 to 2014, with sales likely increasing to just over $4.6 billion. This growth is dependent on new product development and changes in world demographics. Continued demand for products such as propofol and sevoflurane make it likely that the general anesthesia segment will represent the largest percentage of growth during this period.
2. Sales of anesthesia drugs increased 2.4 percent from 2007 to 2009, primarily due to demand in the local anesthesia segment. Advanced delivery methods of anesthesia drugs like lidocaine, and a steady demand for traditional products, led this $1.6 billion market segment.
3. Growth in the market for anesthesia drugs is likely to be affected by safety issues more than the typical competitive issues sometimes seen in less mature pharmaceutical segments. Among the trends are regulation of anesthesia drugs, pediatric applications of anesthesia, allergic reactions in anesthesia, anesthesia and sleep, gender differences in anesthesia reaction, trends in conscious sedation and long-term effects of anesthesia.
4. Among the several hundred companies that are in the anesthesia drug market, generic competition is increasing in the U.S. and Europe. Anesthesia drug companies run the gamut from large pharmaceutical companies to niche pain management and anesthesia drug manufacturers and worldwide generic providers.
5. The global market for anesthesia drugs is estimated to total $4.1 billion in 2009. This is an increase from $3.9 billion in 2007 and $4.06 in 2008.
Learn more about The World Anesthesia Drug Market.
